Autoimmune Dementia

Abstract

Dementia refers to an acquired syndrome of intraindividual cognitive decline that ultimately interferes with an individual's ability to manage their usual duties at work or home. As experience with the diagnosis and management of patients with autoimmune and paraneoplastic encephalitis (AE) has expanded, it has become increasingly apparent that dementia may arise as a subacute or chronic complication of immune-mediated injury to the central nervous system. Progressive memory and thinking problems may represent the first (or only) sign of an underlying autoimmune or paraneoplastic disease. Accordingly, there is a need to routinely consider the diagnosis of AE in patients with dementia, and to evaluate patients recovering from AE for clinically meaningful cognitive impairment. We review and summarize the available evidence concerning the diagnosis and care of AE patients with associated cognitive impairment, herein referred to as autoimmune dementia (AiD). Relevant information is used to propose a novel diagnostic framework that may be applied to improve recognition, and facilitate the expedited evaluation and treatment of patients with AiD.

Keywords

autoimmune encephalitis - encephalopathy - dementia - neurodegenerative illness

• References

• 1 Venkatesan A, Tunkel AR, Bloch KC. , et al; International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013; 57 (08) 1114-1128
• 2 George BP, Schneider EB, Venkatesan A. Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010. PLoS One 2014; 9 (09) e104169
• 3 Dubey D, Pittock SJ, Kelly CR. , et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol 2018; 83 (01) 166-177
• 4 McKeon A. Autoimmune encephalopathies and dementias. Continuum (Minneap Minn) 2016; 22 (2 Dementia(: 538-558
• 5 Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci 2015; 1338: 94-114
• 6 Bauer J, Bien CG. Neuropathology of autoimmune encephalitides. In: Pittock SJ, Vincent A. , eds. Handbook of Clinical Neurology. Vol 133. Autoimmune Neurology. Amsterdam, Netherlands: Elsevier; 2016: 107-120
• 7 Graus F, Titulaer MJ, Balu R. , et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15 (04) 391-404
• 8 Titulaer MJ, McCracken L, Gabilondo I. , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
• 9 Flanagan EP, McKeon A, Lennon VA. , et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010; 85 (10) 881-897
• 10 McKeon GL, Robinson GA, Ryan AE. , et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: a systematic review. J Clin Exp Neuropsychol 2018; 40 (03) 234-252
• 11 Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry 2012; 83 (02) 195-198
• 12 Finke C, Prüss H, Heine J. , et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with Leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017; 74 (01) 50-59
• 13 Dalmau J, Gleichman AJ, Hughes EG. , et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
• 14 Iizuka T, Kaneko J, Tominaga N. , et al. Association of progressive cerebellar atrophy with long-term outcome in patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2016; 73 (06) 706-713
• 15 Kataoka H, Sawa N, Tonomura Y, Ueno S. Early progression of brain atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis: case reports. Medicine (Baltimore) 2017; 96 (17) e6776
• 16 Finke C, Kopp UA, Pajkert A. , et al. Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis. Biol Psychiatry 2016; 79 (09) 727-734
• 17 Brier MR, Day GS, Snyder AZ, Tanenbaum AB, Ances BM. N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI. J Neurol 2016; 263 (06) 1083-1091
• 18 Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study. Lancet Psychiatry 2017; 4 (10) 768-774
• 19 Finke C, Kopp UA, Scheel M. , et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2013; 74 (02) 284-296
• 20 Lai M, Hughes EG, Peng X. , et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65 (04) 424-434
• 21 Hughes EG, Peng X, Gleichman AJ. , et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30 (17) 5866-5875
• 22 Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 76 (01) 108-119
• 23 McKhann GM, Knopman DS, Chertkow H. , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (03) 263-269
• 24 American Psychiatric Association. Neurocognitive Disorders. In: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. doi.org/10.1176/appi.books.9780890425596.dsm17; 2013
• 25 Marquetand J, van Lessen M, Bender B. , et al. Slowly progressive LGI1 encephalitis with isolated late-onset cognitive dysfunction: a treatable mimic of Alzheimer's disease. Eur J Neurol 2016; 23 (05) e28-e29
• 26 Butler CR, Miller TD, Kaur MS. , et al. Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex. J Neurol Neurosurg Psychiatry 2014; 85 (04) 387-391
• 27 Flanagan EP, Drubach DA, Boeve BF. Autoimmune dementia and encephalopathy. Handb Clin Neurol 2016; 133: 247-267
• 28 McKeon A, Lennon VA, Pittock SJ. Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn) 2010; 16 (2 Dementia): 80-101
• 29 McKeon A. Immunotherapeutics for autoimmune encephalopathies and dementias. Curr Treat Options Neurol 2013; 15 (06) 723-737
• 30 Graus F, Ribalta T, Campo E, Monforte R, Urbano A, Rozman C. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology 1990; 40 (02) 219-222
• 31 Verschuuren J, Chuang L, Rosenblum MK. , et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 1996; 91 (05) 519-525
• 32 Dalmau J, Gultekin SH, Voltz R. , et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 (Pt 1): 27-39
• 33 Bien CG, Vincent A, Barnett MH. , et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135 (Pt 5): 1622-1638
• 34 Greenlee JE, Clawson SA, Hill KE. , et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation 2014; 11: 160
• 35 Greenlee JE, Clawson SA, Hill KE. , et al. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One 2015; 10 (04) e0123446
• 36 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77 (02) 179-189
• 37 Lancaster E, Dalmau J. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012; 8 (07) 380-390
• 38 Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F. Neurons as targets for T cells in the nervous system. Trends Neurosci 2013; 36 (06) 315-324
• 39 Zekeridou A, Lennon VA. Memory in autoimmune NMDA receptor encephalitis: an issue for B cells and patients. Brain 2016; 139 (Pt 10): 2581-2583
• 40 Lai M, Huijbers MGM, Lancaster E. , et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9 (08) 776-785
• 41 Planagumà J, Leypoldt F, Mannara F. , et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138 (Pt 1): 94-109
• 42 Klang A, Schmidt P, Kneissl S. , et al. IgG and complement deposition and neuronal loss in cats and humans with epilepsy and voltage-gated potassium channel complex antibodies. J Neuropathol Exp Neurol 2014; 73 (05) 403-413
• 43 Prüss H, Leubner J, Wenke NK, Czirják GÁ, Szentiks CA, Greenwood AD. Anti-NMDA receptor encephalitis in the polar bear (Ursus maritimus) knut. Sci Rep 2015; 5: 12805
• 44 unknown unknown. Article in this issue. Semin Neurol 2018
• 45 Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev 2017; 97 (02) 839-887
• 46 Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. Nat Rev Neurosci 2016; 17 (02) 103-117
• 47 van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19 (05) 604-607
• 48 Gadoth A, Pittock SJ, Dubey D. , et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017; 82 (01) 79-92
• 49 Hara M, Ariño H, Petit-Pedrol M. , et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 2017; 88 (14) 1340-1348
• 50 Spatola M, Petit-Pedrol M, Simabukuro MM. , et al. Investigations in GABA_A receptor antibody-associated encephalitis. Neurology 2017; 88 (11) 1012-1020
• 51 Höftberger R, Titulaer MJ, Sabater L. , et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013; 81 (17) 1500-1506
• 52 Day GS. Rethinking outcomes in Leucine-rich, glioma-inactivated 1 protein encephalitis: “Good” isn't good enough. JAMA Neurol 2017; 74 (01) 19-21
• 53 McKeon GL, Scott JG, Spooner DM. , et al. Cognitive and social functioning deficits after anti-N-methyl-D-aspartate receptor encephalitis: an exploratory case series. J Int Neuropsychol Soc 2016; 22 (08) 828-838
• 54 Frisch C, Malter MP, Elger CE, Helmstaedter C. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol 2013; 20 (09) 1297-1304
• 55 Ariño H, Armangué T, Petit-Pedrol M. , et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016; 87 (08) 759-765
• 56 van Sonderen A, Ariño H, Petit-Pedrol M. , et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016; 87 (05) 521-528
• 57 Joubert B, Saint-Martin M, Noraz N. , et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 2016; 73 (09) 1115-1124
• 58 van Sonderen A, Thijs RD, Coenders EC. , et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016; 87 (14) 1449-1456
• 59 Tobin WO, Lennon VA, Komorowski L. , et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83 (20) 1797-1803
• 60 Dogan Onugoren M, Deuretzbacher D, Haensch CA. , et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 2015; 86 (09) 965-972
• 61 Joubert B, Kerschen P, Zekeridou A. , et al. Clinical spectrum of encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 2015; 72 (10) 1163-1169
• 62 Höftberger R, van Sonderen A, Leypoldt F. , et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015; 84 (24) 2403-2412
• 63 Lancaster E, Lai M, Peng X. , et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9 (01) 67-76
• 64 Hébert J, Day G, Steriade C, Wennberg R, Tang-Wai D. Long-term cognitive outcomes in patients with autoimmune encephalitis. Can J Neurol Sci 2018; In press
• 65 Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997; 24 (03) 318-328
• 66 Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71 (02) 59-72
• 67 Graus F, Keime-Guibert F, Reñe R. , et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (Pt 6): 1138-1148
• 68 Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53 (05) 580-587
• 69 Luque FA, Furneaux HM, Ferziger R. , et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29 (03) 241-251
• 70 Pittock SJ, Parisi JE, McKeon A. , et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 2010; 67 (09) 1109-1115
• 71 Voltz R, Gultekin SH, Rosenfeld MR. , et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340 (23) 1788-1795
• 72 Dalmau J, Graus F, Villarejo A. , et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127 (Pt 8): 1831-1844
• 73 Sillevis Smitt P, Grefkens J, de Leeuw B. , et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002; 249 (06) 745-753
• 74 Keime-Guibert F, Graus F, Fleury A. , et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68 (04) 479-482
• 75 Graus F, Vega F, Delattre JY. , et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992; 42 (3, Pt 1): 536-540
• 76 Shaw PJ, Walls TJ, Newman PK, Cleland PG, Cartlidge NE. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers--report of 5 cases. Neurology 1991; 41 (2, Pt 1): 228-233
• 77 Chong JY, Rowland LP. What's in a NAIM? Hashimoto encephalopathy, steroid-responsive encephalopathy associated with autoimmune thyroiditis, or nonvasculitic autoimmune meningoencephalitis?. Arch Neurol 2006; 63 (02) 175-176
• 78 Castillo PR, Boeve BF, Caselli RJ. , et al. Steroid-responsive encephalopathy associated with thyroid autoimmunity: clinical and laboratory findings. Neurology 2002; 58 (Suppl. 03) A248
• 79 Laurent C, Capron J, Quillerou B. , et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev 2016; 15 (12) 1129-1133
• 80 Caselli RJ, Boeve BF, Scheithauer BW, O'Duffy JD, Hunder GG. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology 1999; 53 (07) 1579-1581
• 81 Lyons MK, Caselli RJ, Parisi JE. Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. J Neurosurg 2008; 108 (05) 1024-1027
• 82 Brooks BL, Barlow KM. A methodology for assessing treatment response in Hashimoto's encephalopathy: a case study demonstrating repeated computerized neuropsychological testing. J Child Neurol 2011; 26 (06) 786-791
• 83 Mazzù I, Mosti S, Caltagirone C, Carlesimo GA. Hashimoto's encephalopathy: neuropsychological findings. Neurol Sci 2012; 33 (03) 653-656
• 84 Wang J, Zhang J, Xu L, Shi Y, Wu X, Guo Q. Cognitive impairments in Hashimoto's encephalopathy: a case-control study. PLoS One 2013; 8 (02) e55758
• 85 Sabbah-Talasazan L, Piryatinsky I. Neuropsychological impairment in Hashimoto's encephalopathy: a case report and literature review. Appl Neuropsychol Adult 2017; ; (May): 1-9
• 86 Çoban A, Ismail Küçükali C, Bilgiç B. , et al. Evaluation of incidence and clinical features of antibody-associated autoimmune encephalitis mimicking dementia. Behav Neurol 2014; 2014: 935379
• 87 Escudero D, Guasp M, Ariño H. , et al. Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology 2017; 89 (14) 1471-1475
• 88 Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol 2008; 65 (11) 1502-1508
• 89 Miller ZA, Sturm VE, Camsari GB. , et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: completing the picture. Neurol Neuroimmunol Neuroinflamm 2016; 3 (06) e301
• 90 McKeon A. Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist 2013; 3 (02) 53-64
• 91 Szots M, Blaabjerg M, Orsi G. , et al. Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: a prospective multimodal MRI study. J Neurol Sci 2017; 376: 159-165
• 92 Do L-D, Chanson E, Desestret V. , et al. Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. Neurology 2017; 88 (06) 514-524
• 93 Zetterberg H. Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017; 43 (03) 194-199
• 94 Iizuka T, Yoshii S, Kan S. , et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol 2010; 257 (10) 1686-1691
• 95 Wei Y-C, Liu C-H, Lin J-J. , et al. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 2013; 261 (1-2): 129-133
• 96 Gelpi E, Höftberger R, Graus F. , et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132 (04) 531-543
• 97 Sabater L, Gaig C, Gelpi E. , et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13 (06) 575-586
• 98 Gaig C, Graus F, Compta Y. , et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017; 88 (18) 1736-1743
• 99 Honorat JA, Komorowski L, Josephs KA. , et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017; 4 (05) e385
• 100 Haitao R, Yingmai Y, Yan H. , et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol 2016; 300: 9-10
• 101 Schröder JB, Melzer N, Ruck T. , et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm 2016; 4 (01) e302
• 102 Bonello M, Jacob A, Ellul MA. , et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm 2017; 4 (05) e383
• 103 Tüzün E, Rossi JE, Karner SF, Centurion AF, Dalmau J. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. J Neuroimmunol 2007; 186 (1-2): 177-180
• 104 Tobin WO, Popescu BF, Lowe V. , et al. Multiple sclerosis masquerading as Alzheimer-type dementia: clinical, radiological and pathological findings. Mult Scler 2016; 22 (05) 698-704
• 105 Rocca MA, Amato MP, De Stefano N. , et al; MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015; 14 (03) 302-317
• 106 Giovannoni G. Should we rebrand multiple sclerosis a dementia?. Mult Scler Relat Disord 2017; 12: 79-81
• 107 De Maindreville A, Bedos L, Bakchine S. Systemic sarcoidosis mimicking a behavioural variant of frontotemporal dementia. Case Rep Neurol Med 2015; 2015: 409126
• 108 Kiesmann M, Lang PO, Clere R, Bousiges O, Vogel T, Kaltenbach G. Sarcoidosis presenting as late-onset dementia: are cerebrospinal fluid biomarkers analyses helpful?. J Am Geriatr Soc 2015; 63 (01) 198-200
• 109 Schielke E, Nolte C, Müller W, Brück W. Sarcoidosis presenting as rapidly progressive dementia: clinical and neuropathological evaluation. J Neurol 2001; 248 (06) 522-524
• 110 Bönstrup M, Ott K, Glatzel M, Magnus T. Frontal lobe dementia syndrome as a first manifestation of primary angiitis of the central nervous system (PACNS). Clin Neurol Neurosurg 2016; 141: 92-94
• 111 Hajj-Ali RA, Calabrese LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun 2014; ;48-49: 149-152
• 112 Salvarani C, Brown Jr RD, Hunder GG. Adult primary central nervous system vasculitis. Lancet 2012; 380 (9843): 767-777
• 113 Danve A, Grafe M, Deodhar A. Amyloid beta-related angiitis--a case report and comprehensive review of literature of 94 cases. Semin Arthritis Rheum 2014; 44 (01) 86-92
• 114 Roessler-Górecka M, Mendel T, Wiśniowska J, Seniów J. Neuropsychological characteristics of encephalopathy in Susac's syndrome - case report. Neurol Neurochir Pol 2017; 51 (02) 174-179
• 115 LeMonda BC, Peck CP, Giles KJ, Bowers D. Neurocognitive profile of a woman with Susac's syndrome: further evidence of cognitive variability. Clin Neuropsychol 2015; 29 (05) 689-706
• 116 Varadkar S, Cross JH. Rasmussen syndrome and other inflammatory epilepsies. Semin Neurol 2015; 35 (03) 259-268
• 117 Varadkar S, Bien CG, Kruse CA. , et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014; 13 (02) 195-205
• 118 Lin Y-R, Chou L-C, Chen H-C, Liou TH, Huang SW, Lin HW. Increased risk of dementia in patients with systemic lupus erythematosus: a nationwide population-based cohort study. Arthritis Care Res (Hoboken) 2016; 68 (12) 1774-1779
• 119 Singh D, Takács A. Primary cerebral lupus as a cause of reversible cognitive impairment. Aust N Z J Psychiatry 2013; 47 (10) 968-969
• 120 Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus 1995; 4 (06) 482-485
• 121 Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Bartkiewicz P, Dmochowski M. Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department. Aging Clin Exp Res 2016; 28 (04) 659-663
• 122 Adair JC. Dementia associated with antiphospholipid antibodies. Rheumatology (Oxford) 2006; 45 (02) 241-242 , author reply 242–243
• 123 Ungprasert P, Wijarnpreecha K, Thongprayoon C. Rheumatoid arthritis and the risk of dementia: a systematic review and meta-analysis. Neurol India 2016; 64 (01) 56-61
• 124 Wotton CJ, Goldacre MJ. Associations between specific autoimmune diseases and subsequent dementia: retrospective record-linkage cohort study, UK. J Epidemiol Community Health 2017; 71 (06) 576-583
• 125 Knopman DS, DeKosky ST, Cummings JL. , et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56 (09) 1143-1153
• 126 Simabukuro MM, Sabater L, Adoni T. , et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm 2015; 2 (04) e136
• 127 Dalmau J, Tüzün E, Wu HY. , et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61 (01) 25-36
• 128 López-Chiriboga AS, Flanagan EP. Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders.
• 129 Varley J, Taylor J, Irani SR. Autoantibody-mediated diseases of the CNS: structure, dysfunction and therapy. Neuropharmacology 2018; 132: 71-82
• 130 Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol 2014; 13 (08) 788-794
• 131 Livingston G, Sommerlad A, Orgeta V. , et al. Dementia prevention, intervention, and care. Lancet 2017; 390 (10113): 2673-2734
• 132 Peters R, Beckett N, Forette F. , et al; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7 (08) 683-689
• 133 Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. Int Psychogeriatr 2014; 26 (01) 9-18
• 134 Fiatarone Singh MA, Gates N, Saigal N. , et al. The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc 2014; 15 (12) 873-880
• 135 Krell-Roesch J, Vemuri P, Pink A. , et al. Association between mentally stimulating activities in late life and the outcome of incident mild cognitive impairment, with an analysis of the APOE ε4 genotype. JAMA Neurol 2017; 74 (03) 332-338
• 136 Valls-Pedret C, Sala-Vila A, Serra-Mir M. , et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med 2015; 175 (07) 1094-1103
• 137 Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010; 75 (01) 27-34
• 138 Lutsey PL, Misialek JR, Mosley TH. , et al. Sleep characteristics and risk of dementia and Alzheimer's disease: the atherosclerosis risk in communities study. Alzheimers Dement 2018; 14 (02) 157-166
• 139 Britt DMI, Day GS. Over-prescribed medications, under-appreciated risks: a review of the cognitive effects of anticholinergic medications in older adults. Mo Med 2016; 113 (03) 207-214
• 140 Gray SL, Anderson ML, Dublin S. , et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175 (03) 401-407
• 141 Reus VI, Fochtmann LJ, Eyler AE. , et al. The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016; 173 (05) 543-546
• 142 Spector A, Thorgrimsen L, Woods B. , et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 2003; 183: 248-254
• 143 Amieva H, Robert PH, Grandoulier A-S. , et al. Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. Int Psychogeriatr 2016; 28 (05) 707-717
• 144 Bradley L. Rehabilitation following anti-NMDA encephalitis. Brain Inj 2015; 29 (06) 785-788
• 145 Bach LJ. Long term rehabilitation management and outcome of anti-NMDA receptor encephalitis: case reports. NeuroRehabilitation 2014; 35 (04) 863-875
• 146 Guo Y-H, Kuan T-S, Hsieh P-C, Lien WC, Chang CK, Lin YC. Rehabilitation for a child with recalcitrant anti-N-methyl-d-aspartate receptor encephalitis: case report and literature review. Neuropsychiatr Dis Treat 2014; 10: 2263-2267
• 147 Tham S-L, Kong K-H. A case of anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis: a rehabilitation perspective. NeuroRehabilitation 2012; 30 (02) 109-112
• 148 Burke WJ, Miller JP, Rubin EH. , et al. Reliability of the Washington University Clinical Dementia Rating. Arch Neurol 1988; 45 (01) 31-32
• 149 Constantinescu R, Krýsl D, Andrén K. , et al. Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. J Neuroimmunol 2017; 306: 25-30
• 150 Planagumà J, Haselmann H, Mannara F. , et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol 2016; 80 (03) 388-400
• 151 Warikoo N, Brunwasser SJ, Benz A. , et al. Positive allosteric modulation as a potential therapeutic strategy in anti-NMDA receptor encephalitis. J Neurosci 2018; 38 (13) 3218-3229
• 152 Dale RC, Brilot F, Duffy LV. , et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83 (02) 142-150
• 153 Scheibe F, Prüss H, Mengel AM. , et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88 (04) 366-370
• 154 Sunderland T, Hill JL, Mellow AM. , et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989; 37 (08) 725-729
• 155 Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive ‘vital signs’ measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000; 15 (11) 1021-1027
• 156 Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23 (10) 433-441
• 157 Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983; 140 (06) 734-739
• 158 Nasreddine ZS, Phillips NA, Bédirian V. , et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53 (04) 695-699
• 159 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (03) 189-198
• 160 Tariq SH, Tumosa N, Chibnall JT, Perry III MH, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder--a pilot study. Am J Geriatr Psychiatry 2006; 14 (11) 900-910
• 161 Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21 (11) 1078-1085